The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or VenetoclaxAlexandria P. Eiken, Dalia El‐Gamal|Hemato|2024Cited by 2
Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effectsAlexandria P. Eiken, Dalia El‐Gamal|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 0